<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYCODAN- hydrocodone bitartrate and homatropine methylbromideÂ tabletÂ </strong><br><strong>HYCODAN- hydrocodone bitartrate and homatropine methylbromideÂ syrupÂ </strong><br>Endo Pharmaceuticals Inc.<br></p></div>
<h1>
<span class="Bold">ANTITUSSIVE<br><br>HYCODAN<span class="Sup">Â®</span><br></span>(Hydrocodone Bitartrate and
        Homatropine Methylbromide)<br><span class="Bold">TABLETS AND
                SYRUP<br><br>CIII<br><br>R<span class="Sub">x</span> only</span>
</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="A9ED2C0A-B992-4DB3-A4A9-197F96F76B0E"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">HYCODAN contains hydrocodone (dihydrocodeinone) bitartrate, a
                            semisynthetic centrally-acting opioid antitussive. Homatropine
                            methylbromide is included in a subtherapeutic amount to discourage
                            deliberate overdosage.</p>
<p>Each HYCODAN tablet or teaspoonful (5 mL) contains:<br>
                        Hydrocodone Bitartrate,
                            USPÂ Â Â Â Â Â Â Â Â Â Â Â Â 5 mg<br>
                        Homatropine Methylbromide,
                            USPÂ Â Â Â Â 1.5 mg</p>
<p>HYCODAN tablets also contain: calcium phosphate dibasic,
                            colloidal silicon dioxide, lactose, magnesium stearate, starch and
                            stearic acid.</p>
<p>HYCODAN syrup also contains: caramel coloring, FD&amp;C Red
                            40, liquid sugar, methylparaben, propylparaben, sorbitol solution and
                            wild cherry imitation flavor.
                        The hydrocodone component is
                            4,5Î±-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1)
                            hydrate (2:5), a fine white crystal or crystalline powder, which is
                            derived from the opium alkaloid, thebaine, has a molecular weight of
                            (494.50), and may be represented by the following structural formula:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08BB4884-403B-4163-BEE7-5AA40992AC4E&amp;name=hycodan-figure-1.jpg"></p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=08BB4884-403B-4163-BEE7-5AA40992AC4E&amp;name=hycodan-figure-2.jpg"></p>
<p>Homatropine methylbromide is 8-Azoniabicyclo
                            [3.2.1]octane,3-[(hydroxyphenyl-acetyl)oxy]-8,8-dimethyl-,bromide,
                            endo-; a white crystal or fine white crystalline powder, with a
                            molecular weight of (370.29).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="DCD71716-C38D-4A9A-BE7A-6DD19BE60598"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Hydrocodone is a semisynthetic opioid antitussive and analgesic
                            with multiple actions qualitatively similar to those of codeine. The
                            precise mechanism of action of hydrocodone and other opiates is not
                            known; however, hydrocodone is believed to act directly on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>
                            center. In excessive doses, hydrocodone, like other opium derivatives,
                            will depress respiration. The effects of hydrocodone in therapeutic
                            doses on the cardiovascular system are insignificant. Hydrocodone can
                            produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, physical and physiological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Following a 10 mg oral dose of hydrocodone administered to five
                            adult male subjects, the mean peak concentration was 23.6 Â± 5.2                     ng/mL. Maximum serum levels were achieved at 1.3 Â± 0.3 hours
                            and the half-life was determined to be 3.8 Â± 0.3 hours.
                            Hydrocodone exhibits a complex pattern of metabolism including
                            O-demethylation, N-demethylation and 6-keto reduction to the
                            corresponding 6-Î±- and
                        6-Î²-hydroxymetabolites.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="E0E356BD-3976-47B7-AB77-C67BC113A6D8"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">HYCODAN (hydrocodone bitartrate and homatropine methylbromide) is
                            indicated for the symptomatic relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="B78B335F-4CBD-4E2C-B9D6-CC6F228E85CB"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">HYCODAN should not be administered to patients who are
                            hypersensitive to hydrocodone or homatropine methylbromide.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="AD2DC6B2-A88F-4470-951B-D5FBB0BF05A4"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and,                         therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>,
                            physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance may develop upon repeated
                            administration of HYCODAN and it should be prescribed and administered
                            with the same degree of caution appropriate to the use of other opioid
                            drugs (see <span class="Bold"><a href="#BB7A2A66-E93F-4998-ADDB-61DCAB8AC646">DRUG ABUSE
                                    AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="D6CA9381-BFC1-453D-8499-54C4BA89273B"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">HYCODAN produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by
                                    directly acting on brain stem respiratory centers. If
                                    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it may be antagonized by the use
                                    of naloxone hydrochloride and other supportive measures when
                                    indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="B7D9F37B-4DAC-4F99-969B-E337D145D7A4"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> properties of opioids and              their capacity to elevate cerebrospinal fluid pressure may be
                                    markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other
                                    intracranial lesions or a pre-existing increase in intracranial
                                    pressure. Furthermore, opioids produce adverse reactions which
                                    may obscure the clinical course of patients with head
                                injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CDC17F58-1746-4BA2-8902-C79ECD73EFC6"></a><a name="section-6.3"></a><p></p>
<h2>Acute Abdominal Conditions</h2>
<p class="First">The administration of HYCODAN or other opioids may
                                    obscure the diagnosis or clinical course of patients with acute
                                    abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="D4EE6D12-9366-4971-B745-134FD02677A9"></a><a name="section-6.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">In young pediatric patients, as well as adults, the         respiratory center is sensitive to the depressant action of
                                    opioid <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> suppressants in a dose-dependent manner. Benefit to
                                    risk ratio should be carefully considered especially in the
                                    pediatric population with respiratory embarrassment (e.g.,
                                    <span class="product-label-link" type="condition" conceptid="260134" conceptname="Croup">croup</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="A21C5E39-EEE4-4EBC-B678-C67D72F1F015"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="E01EE04A-3CBD-466D-B950-9169002C41F2"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Before prescribing medication to suppress or modify
                                    <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, it is important to ascertain that the underlying cause of
                                    <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> is identified, that modification of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> does not
                                    increase the risk of clinical or physiological complications,
                                    and that appropriate therapy for the primary disease is
                                    provided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="D95A5B55-3405-4CED-A472-04769356126B"></a><a name="section-7.2"></a><p></p>
<h2>Special Risk Patients</h2>
<p class="First">HYCODAN (hydrocodone bitartrate and homatropine
                                    methylbromide) should be given with caution to certain patients
                                    such as the elderly or debilitated, and those with severe
                                    impairment of hepatic or renal functions, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>,
                                    Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or urethral
                                    stricture, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="B093367F-0A95-4187-9F77-F275480EACA7"></a><a name="section-7.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Hydrocodone may impair the mental and/or physical
                                    abilities required for the performance of potentially hazardous
                                    tasks such as driving a car or operating machinery. The patient
                                    using HYCODAN should be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="EB9D64F1-3B14-4C00-89AE-C4182DB0AA2F"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Patients receiving opioids, antihistamines,
                                    antipsychotics, antianxiety agents or other CNS depressants
                                    (including alcohol) concomitantly with HYCODAN may exhibit an
                                    additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When combined therapy is contemplated,
                                    the dose of one or both agents should be reduced. The use of MAO
                                    inhibitors or tricyclic antidepressants with hydrocodone
                                    preparations may increase the effect of either the
                                    antidepressant or hydrocodone.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="D39CF163-83D3-43D9-A808-46BE6EF1B6E3"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies of HYCODAN in animals to evaluate the
                                    carcinogenic and mutagenic potential and the effect on fertility
                                    have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="AB1B96B2-CF53-42EA-84E4-41896E41E9F2"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="C07987E7-8A2A-4E2E-B15E-2463EF91FF9A"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects: Pregnancy Category C</h3>
<p class="First">Animal reproduction studies have not been
                                            conducted with HYCODAN. It is also not known whether
                                            HYCODAN can cause fetal harm when administered to a
                                            pregnant woman or can affect reproduction capacity.
                                            HYCODAN should be given to a pregnant woman only if
                                            clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="D4A7ED03-B88B-4288-BA5D-FCDD4BA52EF6"></a><a name="section-7.6.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Babies born to mothers who have been taking
                                            opioids regularly prior to delivery will be physically
                                            dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and
                                            excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes,
                                            increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>,
                                            <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the
                                            syndrome does not always correlate with the duration of
                                            maternal opioid use or dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="CC778F49-8648-4D93-99C0-0DC5D63602B3"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">As with all opioids, administration of HYCODAN to the
                                    mother shortly before delivery may result in some degree of
                                    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher
                                    doses are used.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="F0843836-3FF2-46CD-86F0-2E9BA759CA38"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human
                                    milk. Because many drugs are excreted in human milk and because
                                    of the potential for serious adverse reactions in nursing
                                    infants from HYCODAN, a decision should be made whether to
                                    discontinue nursing or to discontinue the drug, taking into
                                    account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="BEE58F0D-06AA-4332-BB00-01779FBCD9C7"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of HYCODAN in pediatric patients
                                    under six have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="D30B19F4-6B33-429F-9150-17E9D202C6D6"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Central Nervous System</span><br>Sedation,
                            <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical
                            performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>,
                            <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>.</p>
<p><span class="Bold">Gastrointestinal System</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
                            and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur; they are more frequent in ambulatory than in
                            recumbent patients. Prolonged administration of HYCODAN may produce
                            <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold">Genitourinary System</span><br>Ureteral
                            spasm, spasm of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> sphincters and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have been
                            reported with opiates.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> </span><br>HYCODAN
                            may produce dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by acting directly on
                            brain stem respiratory centers (see <span class="Bold"><a href="#FAB79A45-765C-4802-8F60-A990970F53A7">OVERDOSAGE</a></span>).</p>
<p><span class="Bold">Dermatological</span><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>,
                            <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="BB7A2A66-E93F-4998-ADDB-61DCAB8AC646"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">HYCODAN (hydrocodone bitartrate and homatropine methylbromide) is
                            a Schedule III opioid. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and
                            tolerance may develop upon repeated administration of opioids;
                            therefore, HYCODAN should be prescribed and administered with caution.
                            However, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is unlikely to develop when HYCODAN is used                for a short time for the treatment of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the
                            condition in which continued administration of the drug is required to
                            prevent the appearance of a withdrawal syndrome, assumes clinically
                            significant proportions only after several weeks of continued oral
                            opioid use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop
                            after a few days of opioid therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="FAB79A45-765C-4802-8F60-A990970F53A7"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="D3097A99-76DE-4C69-9BB2-EF7BEF2A2D13"></a><a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Serious overdosage with hydrocodone is characterized by
                                    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or
                                    tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme
                                    <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle
                                    <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and
                                    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>,
                                    <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. The ingestion of very large
                                    amounts of HYCODAN may, in addition, result in acute homatropine                 <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="E088CDEA-DE76-492D-83AC-742EFDFB5387"></a><a name="section-10.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Primary attention should be given to the reestablishment
                                    of adequate respiratory exchange through provision of a patent
                                    airway and the institution of assisted or controlled
                                    ventilation. The opioid antagonist naloxone hydrochloride is a
                                    specific antidote for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result
                                    from overdosage or unusual sensitivity to opioids including
                                    hydrocodone. Therefore, an appropriate dose of naloxone
                                    hydrochloride should be administered, preferably by the
                                    intravenous route, simultaneously with efforts at respiratory
                                    resuscitation. For further information, see full prescribing
                                    information for naloxone hydrochloride. An antagonist should not
                                    be administered in the absence of clinically significant
                                    <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Oxygen, intravenous fluids, vasopressors
                                    and other supportive measures should be employed as indicated.
                                    Gastric emptying may be useful in removing unabsorbed
                                drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="C1A29C9C-A574-45B4-962B-D7C7AE020586"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="C8585BCF-5F98-4D94-9E91-9C4358C1799D"></a><a name="section-11.1"></a><p></p>
<h2>Adults</h2>
<p class="First">One (1) tablet or one (1) teaspoonful (5 mL) of the syrup
                                    every 4 to 6 hours as needed; do not exceed six (6) tablets or
                                    six (6) teaspoonfuls in 24 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CEC92CCA-F958-4EE3-850C-A26D8D7166E1"></a><a name="section-11.2"></a><p></p>
<h2>Children 6 to 12 Years of Age</h2>
<p class="First">One-half (1/2) tablet or one-half (1/2) teaspoonful (2.5
                                    mL) of the syrup every 4 to 6 hours as needed; do not exceed
                                    three (3) tablets or three (3) teaspoonfuls in 24
                                hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="EB0BCC3E-2405-4508-AA64-916D4E23B7AE"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">HYCODAN is supplied as a white, biconvex tablet, one face
                            bisected and debossed with â€œHYCODANâ€?, and the other
                            face plain, available in:</p>
<p>Bottles of 100Â Â Â Â Â Â Â Â NDC
                            63481-042-70<br>Bottles of 500Â Â Â Â Â Â Â Â NDC
                            63481-042-85</p>
<p>Store tablets at 25Â°C (77Â°F); excursions
                            permitted to 15Â°-30Â°C (59Â°-86Â°F).
                            [See USP Controlled Room Temperature.]</p>
<p>Dispense in a tight, light-resistant container, as defined in the
                            USP, with a child-resistant closure (as required).</p>
<p>HYCODAN is also available as a clear red colored, wild cherry
                            flavored syrup in:</p>
<p>Bottles of one pint Â Â Â Â NDC 63481-234-16</p>
<p>Store syrup at 25Â°C (77Â°F); excursions
                            permitted to 15Â°-30Â°C (59Â°-86Â°F).
                            [See USP Controlled Room Temperature.]</p>
<p>Oral prescription where permitted by state law.</p>
<p>Manufactured for: <br><span class="Bold">Endo
                                Pharmaceuticals Inc.</span><br>Chadds Ford, Pennsylvania 19317</p>
<p>HYCODAN<span class="Sup">Â®</span> is a Registered Trademark of Endo
                            Pharmaceuticals Inc.</p>
<p>Copyright Â© Endo Pharmaceuticals Inc. 2003</p>
<p>Printed in U.S.A. <br>412042/May, 2003</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYCODANÂ 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate and homatropine
                                        methylbromide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63481-042</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Hydrocodone Bitartrate</strong> (hydrocodone) </td>
<td class="formItem"></td>
<td class="formItem">5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Homatropine Methylbromide</strong> (Homatropine) </td>
<td class="formItem"></td>
<td class="formItem">1.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>calcium phosphate dibasic</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>colloidal silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">HYCODAN</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63481-042-70</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63481-042-85</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYCODANÂ 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate and homatropine
                                        methylbromide syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63481-234</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Hydrocodone Bitartrate</strong> (hydrocodone) </td>
<td class="formItem"></td>
<td class="formItem">5Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Homatropine Methylbromide</strong> (Homatropine) </td>
<td class="formItem"></td>
<td class="formItem">1.5Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>caramel coloring</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Red 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sugar</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sorbitol solution</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>wild cherry imitation flavor</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63481-234-16</td>
<td class="formItem">1 [pt_us] in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Endo Pharmaceuticals Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>08BB4884-403B-4163-BEE7-5AA40992AC4E</div>
<div>Set id: 08BB4884-403B-4163-BEE7-5AA40992AC4E</div>
<div>Version: 1</div>
<div>Effective Time: 20060607</div>
</div>
</div>Â <div class="DistributorName">Endo Pharmaceuticals Inc.</div></p>
</body></html>
